BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, non-Hodgkin lymphoma that remains incurable. Rituximab, an anti-CD20 monoclonal antibody has been the cornerstone of treatment against WM, and its combination with an alkylator, bendamustine, achieves durable remission in treatment-naive patients with sy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/4/2/12 |